Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562
Metrics: PDF 769 views | HTML 980 views | ?
Nianyi Li1, Qinfen Chen1, Jingwen Gu1, Shuang Li1, Guangjie Zhao1, Wei Wang1, Zhicheng Wang1 and Xiaoqin Wang1
1Department of Haematology, Huashan Hospital, Fudan University, Shanghai, China
Xiaoqin Wang, email: email@example.com
Qinfen Chen, email: firstname.lastname@example.org
Keywords: synergistic effect, deferasirox, decitabine, iron chelation therapy, demethylation
Received: June 19, 2016 Accepted: March 14, 2017 Published: March 27, 2017
A multi-center study from the French Myelodysplastic Syndrome (MDS) Group confirmed that iron chelation therapy is an independent prognostic factor that can increase the survival rate of patients who are suffering from transfusion-dependent low-risk MDS. In this study, we aimed to explore this clinical phenomena in vitro, by exploring the synergistic effect of the iron chelator Deferasirox (DFX) and the DNA methyl transferase inhibitor Decitabine (DAC) in the leukemia cell lines SKM-1, THP-1, and K-562. Treatment with both DFX or DAC promoted apoptosis, induced cell cycle arrest, and inhibited proliferation in all three of these cell lines. The combination of DFX and DAC was much greater than the effect of using either drug alone. DFX showed a synergistic effect with DAC on cell apoptosis in all three cell lines and on cell cycle arrest at the G0/G1 phase in K-562 cells. DFX decreased the ROS levels to varying degrees. In contrast, DAC increased ROS levels and an increase in ROS was also noted when the two drugs were used in combination. Treatment of cells with DAC induced re-expression of ABAT, APAF-1, FADD, HJV, and SMPD3, presumably through demethylation. However the combination of DAC and DFX just had strong synergistic effect on the re-expression of HJV.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.